SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17: 15161525.
  • 2
    Cloughesy TF, Filka E, Gillian N, et al. Irinotecan treatment for recurrent glioma using an every three week regimen. Am J Clin Oncol. 2002; 25: 204208.
  • 3
    Prados M, Kuhn J, Yung A, et al. A phase I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 162a.
  • 4
    Merrouche Y, Extra JM, Abigerges D, et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol. 1997; 15: 10801086.
  • 5
    Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995; 13: 210221.
  • 6
    Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994; 86: 446449.